Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

FDA to review ARB cancer link

The Food and Drugs Administration (FDA) has announced that it is conducting a safety review of angiotensin receptor blockers (ARBs) after a recently published study suggested they may be associated with an increased risk of cancer.

This announcement clarifies that:

  • FDA's review is ongoing and the Agency has not concluded that ARBs increase the risk of cancer
  • At this time, FDA believes that the benefits of these medicines continue to outweigh their potential risks
  • FDA recommends that these drugs continue to be used as recommended in their approved labels

The announcement also provides a useful summary of the data reported in the initial meta-analysis including details of several limitations in the analysis.

Action: Clinicians should be aware of this review. Concerned patients can be reassured or changed to angiotensin converting enzyme inhibitors (ACEI) where these drugs have not been tried previously.

Share 'FDA to review ARB cancer link' on Email Share 'FDA to review ARB cancer link' on Delicious Share 'FDA to review ARB cancer link' on Digg Share 'FDA to review ARB cancer link' on Facebook Share 'FDA to review ARB cancer link' on Google+ Share 'FDA to review ARB cancer link' on reddit Share 'FDA to review ARB cancer link' on StumbleUpon Share 'FDA to review ARB cancer link' on Twitter

atomic-wealth

One Comments to “FDA to review ARB cancer link”

  1. [...] has completed a safety review of angiotensin receptor blockers (ARBs) after they were linked with an increased risk of [...]

    Pingback by Prescribing Advice For GPs » FDA Complete ARB Cancer Review — June 6, 2011 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,615 spam comments.

atomic-wealth
fond-illness
summer